Wacker Chemie Ag · XETR:WCH
Wacker Chemie — Wacker Chemie Ag Ord — Q2 2026 Earnings Presentation
17 slides from Wacker Chemie's earnings presentation, Jul 30, 2026
Slide 1: Q2 2026 Conference Call Note
Q2 2026 Conference Call Note Wacker Chemie AG Dr. Christian Hartel (CEO), Dr. Tobias Ohler (CFO) July 30th, 2026
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on man
Slide 3: WACKER Q2 2026 Highlights
WACKER Q2 2026 Highlights Overview Financials Operations Sustainability EBITDA markedly higher on cost measures, PACE cost program clearly supports Q2/26 WACKER wins L’Oréal net income driven by sale of Siltronic shares performance. > €300m in savings targeted and valuation effects. in 2028. Energy
Slide 4: FY 2026 Outlook Updated
FY 2026 Outlook Updated Reported EBITDA In The Range From €625 to 750m FY 2026 Group Outlook 2026 • Sales: Mid-single-digit percentage higher year over year (Prior: HSD% higher) Outlook • Reported EBITDA in the range from €625 to 750m (Prior: €550 to 700m), incl. €37m from capital option effects fro
Slide 5: Q2 2026 EBITDA At €211m Includes Effect From Pensions
Q2 2026 EBITDA At €211m Includes Effect From Pensions, EBITDA Before Specials at €175m Supported By PACE And Volume Profit & loss Q2 2026 Q2 2025 Q2 comments Sales 1,518 1,413 • Sales +7% yoy, Price +2%, Volume/Mix 6%, FX -1%, • EBITDA before Specials at €175m, +53% yoy on PACE Gross profit 256 165
Slide 6: Financials With €1.57bn In Liquidity And €4.18bn In Equity
Financials With €1.57bn In Liquidity And €4.18bn In Equity Balance sheet Assets Balance sheet per 06/30/26 Liabilities €8.4bn €8.7bn €8.4bn €8.7bn Cash & securities: • High level of liquidity at €1.57bn 52% 50% 45% 48% Accounts receivables: • + €208m higher YTD due to seasonality in Chems 12% 11% Pe
Slide 7: Silicones: EBITDA Higher On PACE & Positive Mix Effects
Silicones: EBITDA Higher On PACE & Positive Mix Effects Quarterly figures Q2 Comments Sales (€m) +6% • Sales higher yoy on better pricing and volumes 713 673 708 757 • EBITDA benefited yoy from PACE cost program as well as 602 positive mix effects • Order intake volatile & total order book higher yo
Slide 8: Polymers: EBITDA Higher On PACE And Inventory Effects
Polymers: EBITDA Higher On PACE And Inventory Effects Quarterly figures Sales (€m) Q2 Comments +12% • Sales yoy higher due to prices matching raw material 406 inflation 363 344 312 333 • Volumes slightly up yoy with improved regional mix • EBITDA yoy supported by PACE cost program and Q2 2025 Q3 202
Slide 9: Biosolutions: Sales And EBITDA Improvement YoY
Biosolutions: Sales And EBITDA Improvement YoY Quarterly figures Sales (€m) Q2 Comments +13% • Sales supported by better pricing to offset higher raw 93 100 99 materials 87 89 • Increased project business in BioPharma • EBITDA supported by cost management Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 EBIT
Slide 10: Polysilicon: Strong Semi Demand, Uncertainty In Solar Continues
Polysilicon: Strong Semi Demand, Uncertainty In Solar Continues Quarterly figures Sales (€m) Q2 Comments +3% • Semi volume growth continues yoy 218 197 222 226 226 • Low solar demand • EBITDA supported by cost savings but lower yoy due to lower solar pricing and higher energy costs Q2 2025 Q3 2025 Q
Slide 11: Net Debt At €722m, Siltronic Effect Included
Net Debt At €722m, Siltronic Effect Of +€185m Included In Cash Flow From Investing Year-to-date development of net debt 19 0 193 -30 -18 -722 -886 Net financial debt Cash flow from Cash flow from Dividend paid, Lease liabilities Fx, others Net financial debt 31. Dec. 2025 operating activities invest
Slide 12: Q&A
Q&A WACKER ‘Creating tomorrow’s:solutions
Slide 13: Q2/26 Special Effects
Appendix Q2/26 Special Effects Overview of special effects in 2026 Item Description Appears in Amount Capital option introduced for some defined-benefit €37m Pension EBITDA (Others) pension commitments in Germany Combined effects of WAF valuation recovery and at- Financial Result at-equity result €2
Slide 14: Guidance FY 2026 Updated
Appendix Guidance FY 2026 Updated In €m FY 2025 Outlook 2026 Sales 5,485 Mid-single-digit percentage higher yoy (Prior: HSD% higher) EBITDA 427 In the range from €625 to 750m (Prior: €550 to 700m) EBITDA margin (%) 7.8 Low-double-digit percentage figure Included in EBITDA / EBIT: -103 0 restructurin
Slide 15: Q2 Results
Appendix Q2 Results Year-over-year performance In €m Q2 2026 Q2 2025 % Sales 1,518 1,413 7.4% EBITDA reported 211 114 85% EBITDA-margin 13.9% 8.1% - EBIT 96 -11 - EBIT-margin 6.3% -0.8% - Net income for the period 350 -19 - EPS 6.86 -0.49 - CapEx 59 104 -43% Net cash flow 243 -137 - Net financial de
Slide 16: Segment Performance
Appendix Segment Performance Q2 results for the group and by segment In €m Q2 2026 Q2 2025 Sales EBITDA % Sales EBITDA % Chemicals 1,163 192 16.5 1,077 144 13.4 SILICONES 757 123 16.2 713 104 14.6 POLYMERS 406 69 17.0 363 40 10.9 BIOSOLUTIONS 99 7 7.4 87 5 5.5 POLYSILICON 226 11 5.0 218 34 15.4 Othe
Slide 17: Issuer, Contact and Additional Information
WACKER: Issuer, Contact and Additional Information Investor relations contacts Financial Calendar Sep. 17, 2026 CMD London Joerg Hoffmann, CFA Oct. 29, 2026 Q3 2026 Results Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com Scott McCollister Tel. +49 89 6279 1560 | scott.mccollister@wacker.com Wacker